Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..
PHARMACHOLOGIC EFFECT
The agent that affects the phosphorus-calcium metabolism in the cartilaginous tissue is a high molecular weight mucopolysaccharide. Slows the resorption of bone tissue and reduces calcium loss, accelerates the recovery of bone tissue, inhibits the process of degeneration of cartilaginous tissue. Prevents the compression of connective tissue and plays the role of a kind of lubrication of articular surfaces. With external application slows the progression of osteoarthritis. Normalizes metabolism in hyaline tissue. Stimulates the regeneration of articular cartilage.
PHARMACOKINETICS
With a single admission of the average therapeutic dose, Cmax in plasma is achieved after 3-4 hours, in synovial fluid after 4-5 hours. Bioavailability is 13%. It is excreted by the kidneys within 24 hours.
INDICATIONS
Osteoporosis, paradontopathy, fractures (to accelerate the formation of bone calluses), degenerative-dystrophic diseases of the joints and spine.
DOSING MODE
Inside adults - 1.5-1 g 2 times / day.
Outer - 2 times / day for 2-3 weeks.
SIDE EFFECT
Rarely: allergic reactions.
CONTRAINDICATIONS
Hypersensitivity to chondroitin sulfate, a tendency to bleeding, thrombophlebitis, pregnancy, lactation (breastfeeding).
PREGNANCY AND LACTATION
Chondroitin sulfate is contraindicated in pregnancy and lactation (breastfeeding).
APPLICATION IN ELDERLY PATIENTS
There are clinical data on the use of chondroitin sulfate in elderly patients with atherosclerosis, with a slight decrease in the concentration of cholesterol and triglycerides in the blood plasma.
SPECIAL INSTRUCTIONS
With different forms of paradontopathy, treatment should be continued for at least 3 months.
There are clinical data on the use of chondroitin sulfate in elderly patients with atherosclerosis, with a slight decrease in the concentration of cholesterol and triglycerides in the blood plasma.
